Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00440635
Status:
COMPLETED
Last Update Posted:
2013-04-16
First Post:
2007-02-26
Brief Title:
Expanded Access Protocol EAP to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
Sponsor:
Janssen-Cilag International NV
Organization:
Janssen-Cilag International NV
Organization Data
Organization:
Janssen-Cilag International NV
Class:
INDUSTRY
Study ID:
CR002185
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Janssen-Cilag International NV
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None